Chan Henry Lee Sells 871 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 871 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $270.42, for a total value of $235,535.82. Following the completion of the transaction, the senior vice president directly owned 160 shares in the company, valued at $43,267.20. The trade was a 84.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $310.72, for a total value of $103,159.04.
• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $311.59, for a total value of $103,447.88.

BeOne Medicines Stock Down 1.7%

Shares of NASDAQ ONC traded down $4.56 during mid-day trading on Wednesday, reaching $263.61. 291,079 shares of the company’s stock were exchanged, compared to its average volume of 255,249. The firm has a market capitalization of $28.92 billion, a price-to-earnings ratio of 58.97 and a beta of 0.49. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The business has a fifty day simple moving average of $301.03 and a 200 day simple moving average of $315.60. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $239.25 and a twelve month high of $385.22.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The company had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. As a group, equities analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current fiscal year.

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently bought and sold shares of ONC. Bank of America Corp DE bought a new position in BeOne Medicines in the second quarter worth approximately $67,657,000. Man Group plc purchased a new stake in shares of BeOne Medicines during the second quarter valued at approximately $59,031,000. Capital International Investors increased its position in BeOne Medicines by 3.3% in the third quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock worth $1,716,883,000 after buying an additional 161,052 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in BeOne Medicines in the second quarter worth $38,337,000. Finally, First Trust Advisors LP boosted its holdings in shares of BeOne Medicines by 91.9% in the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after acquiring an additional 115,601 shares during the period. 48.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ONC shares. Royal Bank Of Canada raised their price target on BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Morgan Stanley reissued an “overweight” rating and set a $395.00 price target on shares of BeOne Medicines in a report on Thursday, May 7th. Truist Financial reaffirmed a “buy” rating and issued a $413.00 price objective (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Leerink Partners lifted their price objective on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Finally, Zacks Research raised BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Thursday, June 4th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.